Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 42

Sort by

Sort Order Select

Journal Articles

Health-Related Quality of Life Outcomes in Patients with Myelodysplastic Syndromes with Ring Sideroblasts Treated with Luspatercept in the Medalist Study

Esther Natalie Oliva, MD, Uwe Platzbecker, Guillermo Garcia-Manero, MD, Ghulam J. Mufti, Professor, Valeria Santini, Mikkael A. Sekeres, Rami S. Komrokji, MD, Jeevan K. Shetty, Derek Tang, Shien Guo, Weiqin Liao, George Zhang, Xianwei Ha, Rodrigo Ito, Jennifer Lord-Bessen, Jay T. Backstrom, Pierre Fenaux, MD PhD

Blood (2020) 136 (Supplement 1): 10–12.

https://doi.org/10.1182/blood-2020-136276

Published: 2020

Journal Articles

Investigating the Quality of Life of Patients with Acute Leukemia, with a Focus on Age and Patient-Reported Experience

Zack Pemberton-Whiteley, Samantha Nier, Jan Geissler, Sophie Wintrich, Bregje Verhoeven, Rita I O Christensen, Sam Salek, PhDRPh FFPM MCMS MRPSGB FESCP, Esther Natalie Oliva, MD, Tatyana Ionova, Jennie Bradley, BA, Anne Rosemary Tate

Blood (2020) 136 (Supplement 1): 25–26.

https://doi.org/10.1182/blood-2020-141293

Published: 2020

Journal Articles

Health-Related Quality of Life Outcomes for Patients with Transfusion-Dependent Beta-Thalassemia Treated with Luspatercept in the Believe Trial

Maria Domenica Cappellini, Ali T. Taher, Antonio Piga, MD, Farrukh Shah, Ersi Voskaridou, Vip Viprakasit, John B. Porter, MA, MD, FRCP, FRCPath, Olivier Hermine, Ellis J. Neufeld, Alexis A. Thompson, MD, Derek Tang, Peiwen Yu, Shien Guo, Jeevan K. Shetty, Dimana Miteva, Tatiana Zinger, Jay T. Backstrom, Esther Natalie Oliva, MD

Blood (2020) 136 (Supplement 1): 8–9.

https://doi.org/10.1182/blood-2020-136312

Published: 2020

Journal Articles

CC-486 Reduces Hospitalization and Associated Estimated Costs in Patients with Acute Myeloid Leukemia (AML) in First Remission after Intensive Chemotherapy: Results from the QUAZAR AML-001 Maintenance Trial

Esther Natalie Oliva, MD, Suman Kambhampati, MD, Albert Oriol, Ignazia La Torre, Barry Skikne, MD, C.L. Beach, PharmD, Keshava Kumar, PhD, Qian Dong, DrPH, Clara Chen, Sandip Ranjan, MTech, Zephirin Kiendrebeogo, Msc, PMP, Thorsten Braun, MD PhD

Blood (2020) 136 (Supplement 1): 14–15.

https://doi.org/10.1182/blood-2020-137562

Published: 2020

Journal Articles

Long Term Effects of Eltrombopag Treatment Versus Placebo for Low-Risk Myelodysplastic Syndromes with Thrombocytopenia (EQoL-MDS): Interim Results of a Single-Blind, Randomised, Controlled, Phase 2 Superiority Trial

Blood (2019) 134 (Supplement_1): 3000.

https://doi.org/10.1182/blood-2019-126744

Published: 2019

Journal Articles

Clinical Relevance of Individual Response to Iron Chelation Therapy (ICT) in Patients with Myelodysplastic Syndromes (MDS) and Transfusion Requirement

Blood (2019) 134 (Supplement_1): 3010.

https://doi.org/10.1182/blood-2019-129902

Published: 2019

Journal Articles

Azacitidine for Post-Remission Therapy in Elderly Patients with Acute Myeloid Leukemia : Final Results of the Qoless AZA-Amle Randomized Trial

Blood (2019) 134 (Supplement_1): 117.

https://doi.org/10.1182/blood-2019-125562

Published: 2019

Journal Articles

A Multicenter, Italian Trial of Early Iron Chelation Therapy with Low Dose Deferasirox (Exjade®) in Patients with Low/Intermediate-1 Risk MDS at the Beginning of Transfusional Story

Emanuele Angelucci, MD, Mario Capasso, PhD, Matteo Giovanni Della Porta, MD, Gian Luca Forni, Domenico Girelli, MD, PhD, Esther Natalie Oliva, MD, Federica Pilo, MD, Marino Clavio, MD, Marta Riva, MD, Annamaria Pelizzari, MD, Pasquale Niscola, MD PhD, Daniela Cilloni, MD PhD, Gianni Binotto, MD, Elena Crisà, MD, Valeria Santini, MD

Blood (2019) 134 (Supplement_1): 4256.

https://doi.org/10.1182/blood-2019-125575

Published: 2019

Journal Articles

A Systematic Literature Review on the Burden of Illness in Lower-Risk Transfusion-Dependent Myelodysplastic Syndromes

Sohan Deshpande, Monica Turner, Michael Byrnes, Christopher Pelligra, Amy Rines-MacEachern, Madhura Chitnis, Austin Kulasekararaj, MDMBBS,MRCP,FRCPath, Derek Tang, PhD BSPharm, Jessica Morison, Esther Natalie Oliva, MD

Blood (2019) 134 (Supplement_1): 5838.

https://doi.org/10.1182/blood-2019-124300

Published: 2019

Journal Articles

Identifying Differences in the Quality of Life of Patients with Acute Leukemia: A Global Survey

Zack Pemberton-Whiteley, Esther Natalie Oliva, MD, Jan Geissler, Sophie Wintrich, Sam Salek, PhDRPh FFPM MCMS MRPSGB FESCP, Tatyana Ionova, PhD Professor, Anne Rosemary Tate, Jennie Bradley

Blood (2019) 134 (Supplement_1): 4785.

https://doi.org/10.1182/blood-2019-128818

Published: 2019

Journal Articles

Assessing Needs for Support in MDS Patients

Esther Natalie Oliva, MD, Raqeebah Agberemi, Sophie Wintrich

Blood (2018) 132 (Supplement 1): 2313.

https://doi.org/10.1182/blood-2018-99-112967

Published: 2018

Journal Articles

Translating the Science of Patient Reported Outcomes into Practice: Meaningfulness of HM-PRO Scores in Patients with Hematological Malignancies

Pushpendra Goswami, PhD MSc, BPharm, Esther Natalie Oliva, MD, Tatyana Ionova, PhD, Sam Salek, PhDRPh FFPM MCMS MRPSGB FESCP

Blood (2018) 132 (Supplement 1): 4860.

https://doi.org/10.1182/blood-2018-99-117180

Published: 2018

Journal Articles

Impact of AML on Patients' Lives: The Value of HM-PRO Measurements

Esther Natalie Oliva, MD, Sam Salek, PhDRPh FFPM MCMS MRPSGB FESCP, Pushpendra Goswami, PhD MSc, BPharm, Tatyana Ionova, PhD

Blood (2018) 132 (Supplement 1): 5900.

https://doi.org/10.1182/blood-2018-99-117600

Published: 2018

Journal Articles

Responsiveness and the Minimal Clinically Important Difference for HM-PRO in Patients with Hematological Malignancies

Pushpendra Goswami, PhD MSc, BPharm, Esther Natalie Oliva, MD, Tatyana Ionova, DSc, Sam Salek, PhDRPh FFPM MCMS MRPSGB FESCP

Blood (2018) 132 (Supplement 1): 2294.

https://doi.org/10.1182/blood-2018-99-117094

Published: 2018

Journal Articles

Myelodysplastic Syndromes with Hypocellular Marrow: Clinical Characteristics and Evaluation of Outcome

Blood (2018) 132 (Supplement 1): 1829.

https://doi.org/10.1182/blood-2018-99-118123

Published: 2018

Journal Articles

Surrogate Thresholds for Iron Chelation in Patients with Hematological Malignancies

Esther Natalie Oliva, MD, Sabrina Zappavigna, Irene Santacaterina, Tiziana Moscato, Nicola Arcadi, Patrizia Cufari, Caterina Alati, Aurelio Maggio, MD

Blood (2017) 130 (Supplement 1): 3499.

https://doi.org/10.1182/blood.V130.Suppl_1.3499.3499

Published: 2017

Journal Articles

HM-PRO: A Novel Patient-Reported Outcome Measure in Hematological Malignancy for Use in Clinical Practice

Pushpendra Goswami, PhD MSc, BPharm, Sam Salek, PhDRPh FFPM MCMS MRPSGB FESCP, Tatyana Ionova, PhD, Esther Natalie Oliva, MD, Adele K Fielding, MBBS,PhDFRCP,FRCPath, Marina Karakantza, MD, Saad Al-Ismail, MD, Graham Collins, MD PhD, Stewart McConnell, Catherine Langton, Daniel Jennings, Roger Else, William J. Kell, MD

Blood (2017) 130 (Supplement 1): 2176.

https://doi.org/10.1182/blood.V130.Suppl_1.2176.2176

Published: 2017

Journal Articles

Inadequacy of Ferritin Trends for Predicting Changes in LIC Risk Category in Transfusion Depedent and Well Chelated Patients with Haemoglobinopathies

Angela Vitrano, PhD, Massimiliano Sacco, DR, Rosamaria Rosso, MD, Alessandra Quota, MD, Daniela Fiorino, MD, Esther Natalie Oliva, MD, Calogera Gerardi, MD, Gaetano Roccamo, MD, Vincenzo Spadola, MD, Aldo Filosa, MD, Lorenzo Tesé, MD, Giuseppina Calvaruso, MD, Lorella Pitrolo, MD, Laura Mistretta, DR, Filippo Cassarà, DR, Rosario Di Maggio, MD, Aurelio Maggio, MD

Blood (2017) 130 (Supplement 1): 936.

https://doi.org/10.1182/blood.V130.Suppl_1.936.936

Published: 2017

Journal Articles

An Integrated Analysis of Darbepoetin Alfa (DAR) in the Treatment of Anemia in Patients with Low- or Intermediate-1 (int-1) Risk Myelodysplastic Syndrome (MDS)

Uwe Platzbecker, MD, Argiris Symeonidis, MD PhD, Jeroen Simon Goede, Agnes Guerci-Bresler, Michel Delforge, MDPhD, Esther Natalie Oliva, MD, Jiri Mayer, Prof, MD SCs, Sejal Badre, Bhakti Mehta, Cisio De Oliveira Brandao

Blood (2017) 130 (Supplement 1): 4271.

https://doi.org/10.1182/blood.V130.Suppl_1.4271.4271

Published: 2017

Journal Articles

Higher Versus Standard Doses of Recombinant Erythropoietin for the Treatment of Anemia in Patients with Myelodysplastic Syndromes: Results of a Retrospective Survey from the Italian Registry of Myelodisplastic Syndromes (FISM)

Blood (2016) 128 (22): 4342.

https://doi.org/10.1182/blood.V128.22.4342.4342

Published: 2016

NARROW

Health-Related Quality of Life Outcomes in Patients with Myelodysplastic Syndromes with Ring Sideroblasts Treated with Luspatercept in the Medalist Study

Investigating the Quality of Life of Patients with Acute Leukemia, with a Focus on Age and Patient-Reported Experience

Health-Related Quality of Life Outcomes for Patients with Transfusion-Dependent Beta-Thalassemia Treated with Luspatercept in the Believe Trial

CC-486 Reduces Hospitalization and Associated Estimated Costs in Patients with Acute Myeloid Leukemia (AML) in First Remission after Intensive Chemotherapy: Results from the QUAZAR AML-001 Maintenance Trial

Long Term Effects of Eltrombopag Treatment Versus Placebo for Low-Risk Myelodysplastic Syndromes with Thrombocytopenia (EQoL-MDS): Interim Results of a Single-Blind, Randomised, Controlled, Phase 2 Superiority Trial

Clinical Relevance of Individual Response to Iron Chelation Therapy (ICT) in Patients with Myelodysplastic Syndromes (MDS) and Transfusion Requirement

Azacitidine for Post-Remission Therapy in Elderly Patients with Acute Myeloid Leukemia : Final Results of the Qoless AZA-Amle Randomized Trial

A Multicenter, Italian Trial of Early Iron Chelation Therapy with Low Dose Deferasirox (Exjade®) in Patients with Low/Intermediate-1 Risk MDS at the Beginning of Transfusional Story

A Systematic Literature Review on the Burden of Illness in Lower-Risk Transfusion-Dependent Myelodysplastic Syndromes

Identifying Differences in the Quality of Life of Patients with Acute Leukemia: A Global Survey

Assessing Needs for Support in MDS Patients

Translating the Science of Patient Reported Outcomes into Practice: Meaningfulness of HM-PRO Scores in Patients with Hematological Malignancies

Impact of AML on Patients' Lives: The Value of HM-PRO Measurements

Responsiveness and the Minimal Clinically Important Difference for HM-PRO in Patients with Hematological Malignancies

Myelodysplastic Syndromes with Hypocellular Marrow: Clinical Characteristics and Evaluation of Outcome

Surrogate Thresholds for Iron Chelation in Patients with Hematological Malignancies

HM-PRO: A Novel Patient-Reported Outcome Measure in Hematological Malignancy for Use in Clinical Practice

Inadequacy of Ferritin Trends for Predicting Changes in LIC Risk Category in Transfusion Depedent and Well Chelated Patients with Haemoglobinopathies

An Integrated Analysis of Darbepoetin Alfa (DAR) in the Treatment of Anemia in Patients with Low- or Intermediate-1 (int-1) Risk Myelodysplastic Syndrome (MDS)

Higher Versus Standard Doses of Recombinant Erythropoietin for the Treatment of Anemia in Patients with Myelodysplastic Syndromes: Results of a Retrospective Survey from the Italian Registry of Myelodisplastic Syndromes (FISM)

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only